A imagem mostra a capa de um livro intitulado “Estratégias de Vacinação contra a COVID-19 no Brasil: Capacitação de Profissionais e Discentes de Enfermagem”, que faz parte da Série Enfermagem e Pandemias, volume VI. A capa apresenta uma fotografia em tons de azul de uma mão segurando um frasco de vacina enquanto uma seringa é inserida nele, simbolizando o ato de preparação para a vacinação. Na parte inferior, aparecem os logotipos da SBIm (Sociedade Brasileira de Imunizações) e da ABEn (Associação Brasileira de Enfermagem). O livro é organizado por Tércia Moreira Ribeiro da Silva e Maria da Glória Lima. O design transmite um foco em saúde pública, ciência e enfermagem.
Downloads
Volume
Estratégias de vacinação contra a COVID-19 no Brasil: capacitação de profissionais e discentes de enfermagem
Páginas
41-51
Publicado
janeiro 1, 2021
Séries
Enfermagem e Pandemias
Copyright (c) 2021 Editora ABEn

Como Citar

RESENDE, Carolina Braga de; MAIA, Ana Clara Martins Santos; MALTA, Stella Elizei de Pinho; PEREIRA, Clebson Verissimo da Costa; REZENDE, Barbara Maximino. Vacinas contra a COVID-19: principais plataformas e bases imunológicas. Em: OLIVEIRA, Josineia Leite de (ed.). Estratégias de vacinação contra a COVID-19 no Brasil: capacitação de profissionais e discentes de enfermagem. Enfermagem e PandemiasBrasília, Brasil: Editora ABEn,2021. v. 6p. 41–51. DOI: 10.51234/aben.21.e08.c05. Disponível em: https://editoraaben.emnuvens.com.br/editora/catalog/book/33/chapter/259. Acesso em: 7 jun. 2026.

Vacinas contra a COVID-19: principais plataformas e bases imunológicas

Autores
Tércia Moreira Ribeiro da Silva, Universidade Federal de Minas Gerais; Carolina Braga de Resende, Universidade Federal de Minas Gerais; Ana Clara Martins Santos Maia, Universidade Federal de Minas Gerais; Stella Elizei de Pinho Malta, Universidade Federal de Minas Gerais; Clebson Verissimo da Costa Pereira, Sociedade Brasileira de Imunizações na Paraíba; Barbara Maximino Rezende, Universidade Federal de Minas Gerais
DOI: https://doi.org/10.51234/aben.21.e08.c05
Sinopse

As vacinas contra COVID-19 (do inglês, Corona Virus Disease) foram desenvolvidas e comercializadas em tempo recorde, mas não deixaram de atender às rigorosas etapas de testes pré-clínicos e clínicos para validação da segurança e eficácia(1-2). O curto período de tempo transcorrido desde o sequenciamento do SARS-CoV-2 (do inglês, Severe acute respiratory syndrome coronavirus 2) até a autorização da primeira vacina contra COVID-19 pode ser atribuído a diversos fatores, dentre eles, o conhecimento acumulado durante décadas, desde o desenvolvimento da primeira vacina(2). Além disso, a pandemia do novo Coronavírus mobilizou pesquisadores do mundo todo e favoreceu o estabelecimento de parcerias e o compartilhamento das plataformas anteriormente desenvolvidas para combater os surtos da Síndrome Respiratória Aguda Grave (SARS-CoV), provocada por um Coronavírus identificado na província de Guangdong, na China em 2002, e da Síndrome Respiratória do Oriente Médio (MERS-CoV), identificada na Península Arábica em 2012(2). [...]

Referências

Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. https://doi.org/10.1038/s41577-020-00479-7

Kuter BJ, Offit PA, Poland GA. The development of COVID-19 vaccines in the United States: why and how so fast? Vaccine. 2021;39(18):2491–5. https://doi.org/10.1016/j.vaccine.2021.03.077

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29. https://doi.org/10.1016/S0140-6736(21)00947-8

Leshem E, Wilder-Smith A. COVID-19 vaccine impact in Israel and a way out of the pandemic. Lancet. 2021;397(10287):1783–5. https://doi.org/10.1016/S0140-6736(21)01018-7

Torjesen I. Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions. BMJ. 2021;372:n523. https://doi.org/10.1136/bmj.n523

Dean N. Hospital admissions due to COVID-19 in Scotland after one dose of vaccine. Lancet. 2021;397(10285):1601–3. https://doi.org/10.1016/S0140-6736(21)00765-0

Pevehouse JCW. The COVID-19 Pandemic, International Cooperation, and Populism. Int Organ. 2020;114(S1):E191–212. https://doi.org/10.1017/S0020818320000399

Menezes APR, Moretti B, Reis AAC. O futuro do SUS: impactos das reformas neoliberais na saúde pública: austeridade versus universalidade. Saúde Debate. 2019;43(spe5):58–70. https://doi.org/10.1590/0103-11042019S505

Ministério da Saúde (BR). Plano Nacional de Operacionalização da Vacinação Contra A COVID-19: Brasil Imunizado Somos uma só Nação [Internet]. 5. ed. Brasília: 2021 [cited 2021 Mar 29]. Available from: https://www.gov.br/saude/pt-br/media/pdf/2021/marco/23/planovacinacaocovid_ed5_15-mar-2021_v2.pdf

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–8. https://doi.org/10.1126/science.abb2762

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32. https://doi.org/10.1002/jmv.25685

Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371. https://doi.org/10.1136/bmj.m3862

Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020;55(5). https://doi.org/10.1016/j.ijantimicag.2020.105950

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615–32. https://doi.org/10.1038/s41577-020-00434-6

Forni G, Mantovani A, Moretta L, Rappuoli R, et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39. https://doi.org/10.1038/s41418-020-00720-9

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052

Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies [Internet]. Viruses. 2020 [cited 2021 May 17];12(3):254. Available from: http://www.allelefrequencies.net/

Zepp F. Principles of vaccination. In: Methods in Molecular Biology. Humana Press Inc.; 2016. p57–84. https://doi.org/10.1007/978-1-4939-3387-7_3

Davis EH, Beck AS, Strother AE, Thompson JK, Widen SG, Higgs S, et al. Attenuation of live-attenuated yellow fever 17D vaccine virus is localized to a high-fidelity replication complex. MBio. 2019;10(5). https://doi:10.1128/mBio.02294-19

Schijns V, Fernández‐Tejada A, Barjaktarović Ž, Bouzalas I, Brimnes J, Chernysh S, et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev. 2020;296(1):169–90. https://doi.org/10.1111/imr.12889

Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J [Internet]. 2021 [cited 2021 May 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33936564

Center for Disease and Control. Pfizer-BioNTech COVID-19 Vaccine Preparation and Administration Summary [Internet]. Atlanta, Geórgia, EUA: CDC; 2021 [cited 2021 May 17]. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/prep-and-admin-summary.pdf

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. https://doi:10.1016/S1473-3099(20)30831-8

Wyeth Indústria Farmacêutica Ltda. Bula ComirnatyTM vacina covid-19 [Internet]. 2021 [cited 2021 May 17]. Available from: https://www.pfizer.com.br/sites/default/files/inline-files/Comirnaty_Profissional_de_Saude_06.pdf

Arcturus Therapeutics I. A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults - Full Text View - ClinicalTrials.gov [Internet]. 2021 [cited 2021 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04668339

BioNTech SE. Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals - Full Text View - ClinicalTrials.gov. Natl Inst Health [Internet]. 2020 [cited 2021 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04368728?term=BNT162b2&draw=2#studydesc

Corminaty, Pfizer, Biontech. COMIRNATYTM: Armazenamento da vacina e manuseio seguro do gelo seco [Internet]. Corminaty 2021 [cited 2021 May 17]; Available from: https://www.comirnatyeducation.com.br/resources

Rauch S, Roth N, Schwendt K, Fotin-Mleczek M, Mueller SO, Petsch B. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021;6(1):1–9. https://doi.org/10.1038/s41541-021-00311-w

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389

ModernaTX I. A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age - Full Text View - ClinicalTrials.gov [Internet]. 2021 [cited 2021 May 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT04796896

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med [Internet]. 2020 [cited 2021 May 17];383(25):2439–50. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2027906

Organização Pan-Americana da Saúde (PAHO), Organização Mundial da Saúde (OMS). Perguntas frequentes sobre as vacinas candidatas contra a COVID-19 e os mecanismos de acesso [Internet]. 2021 [cited 2021 May 17]. Available from: https://iris.paho.org/bitstream/handle/10665.2/53248/OPASFPLIMCOVID-19210004_por.pdf?sequence=1&isAllowed=y

Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Vaccines. 2021;6(1):1–17. https://doi.org/10.1038/s41541-021-00292-w

Butantan. Bula da Vacina adsorvida covid-19 (inativada). Sinov. e Inst. Butantan; 2021;1–8.

Yan Z-P, Yang M, Lai C-L. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel) 2021;14(5). http://doi:10.3390/ph14050406

Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, et al. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv 2021;2021.01.26.426986. https://doi.org/10.1101/2021.01.26.426986

García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5):433. https://doi.org/10.3390/vaccines9050433

Shenzhen Kantai Biological Products Co. LTD. A study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), inactivated in healthy adults aged 18 years and older (COVID-19) [Internet]. 2020 [cited 2021 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04510207

World Health Organization (WHO). Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Genebra: 2021 [cited 2021 May 17]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccine